Back to Results
First PageMeta Content
Medicine / Allergology / Immunology / Clinical medicine / Immune system / RTT / Allergen / Allergic rhinitis / Pollen / Allergy / Rhinitis / Desensitization


Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT − Dose assessment for upcoming Phase III trial EPALINGES, Switzerland, December 11, 2014 – Anergis, a company developing proprietary
Add to Reading List

Document Date: 2014-12-15 02:51:18


Open Document

File Size: 577,59 KB

Share Result on Facebook
UPDATE